The Board believes that the current composition of NRC is capable of acting collectively in the best overall interests of
shareholders with reference to nomination and remuneration of Board members. In 2015, the NRC meeting was held as follows:
2 April 2015
10 December 2015
Dato' Kamaruzzaman Abu Kassim
Tan Sri Datin Paduka Siti Sadiah Sheikh Bakir
Datuk Azzat Kamaludin
Zainah Mustafa
x
Remuneration policies and procedures
The Board believes that the levels of remuneration offered by the Group are sufficient to attract Directors of calibre as well
as sufficient experience and talent to contribute to the performance of the Group. The remuneration framework for the
President and Managing Director has the underlying objective of attracting and retaining an Executive Director needed to
manage the Company successfully. The remuneration package of the President and Managing Director is structured to
commensurate with the achievement of corporate targets set by the Board and his individual performance. The Non-
Executive Directors are remunerated based on fixed annual fees approved by the shareholders of the Company.
The details on the remuneration of the Directors are as follows:
Salary and
Others
(RM)
Allowances
and Fees
(RM)
Fees from
Subsidiaries
(RM)
Benefit in
Kind
(RM)
Provision
of ESOS
(e)
(RM)
TOTAL
(RM)
President and Managing Director
Dato’ Amiruddin Abdul Satar
1,241,352 118,500
50,000
21,250 503,100 1,934,202
Executive Director
Aminudin Dawam
93,500
–
201,240 294,740
Non-Independent Non-Executive Directors
Dato’ Kamaruzzaman Abu Kassim
(a)
175,000
–
175,000
Ahamad Mohamad
(a)
87,500
–
87,500
Zulkifli Ibrahim
(a)
93,000
–
93,000
Independent Non-Executive Directors
Zainah Mustafa
116,000
–
201,240 317,240
Datuk Azzat Kamaludin
(c)
106,000
22,500
201,240 329,740
Dr. Kok Chin Leong
(d)
93,600
84,000
201,240 378,840
Dr. Yoong Fook Ngian
(b)
308,000
–
201,240 509,240
Tan Sri Dato’ Dr. Yahya Awang
#
75,800
29,833
201,240 306,873
Tan Sri Datin Paduka Siti Sadiah Sheikh Bakir
392,500
–
21,250 201,240 614,990
(a) Representative of majority shareholders
(b) Received allowance for professional advisory services as Medical Advisory Chairman
(c) Received allowances for appointment as Independent Director of subsidiary hospitals
(d) Received allowances for professional advisory services on implementation of KPJ Clinical Information System (K-CIS)
(e) Represent ESOS granted but yet to be exercised by all Directors as at 31 December 2015. ESOS is computed based on option
price of RM1.0062 per share against the exercise price of RM3.64 per share
# Resigned as Independent Non-Executive Director with effect from 27 August 2015
173
KPJ Healthcare Berhad
Annual Report
2015
